SO'GLIQNI SAQLASHNING YANGI DAVRI-SHAXSIYLASHTIRILGAN TIBBIYOT HAQIDA

https://doi.org/10.5281/zenodo.15245110

Authors

  • Salimova F.B. Mirzo Ulug‘bek nomidagi O‘zbekiston Milliy universitetining Jizzax filiali Author
  • Fattoxova D.O. Mirzo Ulug‘bek nomidagi O‘zbekiston Milliy universitetining Jizzax filiali Author
  • Egamqulova D.S. Mirzo Ulug‘bek nomidagi O‘zbekiston Milliy universitetining Jizzax filiali Author
  • Soatov B.B. Mirzo Ulug‘bek nomidagi O‘zbekiston Milliy universitetining Jizzax filiali Author

Keywords:

genetik, genom, o‘pka saratoni, ekzom, oksaliplatin, xolestrin, biomarkerlar, fluorourasil va irinotecan

Abstract

Bugungi kunda sog‘liqni saqlash tizimi tez sur’atlar bilan rivojlanib, individual yondashuvga asoslangan shaxsiylashtirilgan tibbiyot tamoyillari keng qo‘llanilmoqda. Ushbu yondashuv har bir bemorning genetik, biologik va hayot tarziga oid xususiyatlarini inobatga olib, davolash usullarini moslashtirishga imkon yaratadi. Tezisimizda shaxsiylashtirilgan tibbiyotning mohiyati, uning afzalliklari va rivojlanish istiqbollari tahlil qilinadi.

Downloads

References

Mariantonia Di Sanzo, Luigi Cipolloni, Marina Borro, Raffaele La Russa, Alessandro Santurro, Matteo Scopetti, Maurizio Simmaco and Paola Frati. “Clinical Applications of Personalized Medicine: A New Paradigm and Challenge” Current Pharmaceutical Biotechnology, Volume 18, Issue 3, Mar 2017, p. 194 – 203

Sunil Mathur and Joseph Sutton. “Personalized medicine could transform healthcare” (Review). Biomedical Reports 7: 3-5, 2017

Mukesh Verma. “Personalized Medicine and Cancer” Journal of Personalized Medicine ISSN 2075-4426

Sarasqueta, F.; Lijnshoten, G.; Lemmens, V.E.; Rutten, H.J.; van den Brule, A.J. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol. Diagn. Ther. 2011, 15, 277–283.

Castillo-Fernandez, O.; Santibanez, M.; Bauza, A.; Calderillo, G.; Castro, C.; Herrera, R.; Serrano, A.; Arrieta, O.; Herrera, L.A. Methylenetetrahydrofolatereductase polymorphism (677 J. Pers. Med. 2012, 2 13 C-T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid. Arch. Med. Res. 2010, 41, 430–433.

Boni, V.; Zarate, R.; Villa, J.C.; Bandrés, E.; Gomez, M.A.; Maiello, E.; Garcia-Foncillas, J.; Aranda, E. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics 2011, 11, 429–436

Downloads

Published

2025-03-28

Issue

Vol. 1 No. 1 (2025): “Biotexnologiyaning rivojlanish istiqbollari va muammolari” mavzusidagi rеspublika ilmiy anjumani

Section

SECTION 2.

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Salimova , F., Fattoxova , D., Egamqulova , D., & Soatov , B. (2025). SO’GLIQNI SAQLASHNING YANGI DAVRI-SHAXSIYLASHTIRILGAN TIBBIYOT HAQIDA: https://doi.org/10.5281/zenodo.15245110. International Scientific and Practical Conference, 1(1), 164-166. https://bestjournalup.com/index.php/ispc/article/view/1348

Most read articles by the same author(s)

1 2 > >>